Skip to main content

Table 2 Performance of the AP4 relapse test in validation cohorts

From: Low expression of a few genes indicates good prognosis in estrogen receptor positive breast cancer

Cohort % AP4- 5 year survival
(95% CI)
10 year survival
(95% CI)
Hazard ratio
(95% CI)
Logrank
p-value
OXFD+ 38% 0.96 (0.90 – 1.00) 0.93 (0.86 – 1.00) 6.73 (2.02 – 22.4) 3 × 10-4
MZ+ 47% 0.92 (0.86 – 0.98) 0.85 (0.75 – 0.95) 2.23 (1.02 – 4.87) 0.039
GUYT+ 31% 0.96 (0.89 – 1.00) 0.88 (0.76 – 1.00) 3.09 (0.90 – 10.5) 0.058
GUYT2+ 36% No metastases in AP4-    
TOTAL 40% 0.95 (0.93 – 0.98) 0.89 (0.85 – 0.93) 3.76 (2.16 – 6.56) 5.14 × 10-7
  1. The 5 and 10 year metastsis-free survival probabilities for the AP4- groups in the validation cohorts, the hazard ratio for AP4- to AP4+, and the logrank p-value.